China Monoclonal Antibody Research Report, 2014

1
Research on China Monoclonal Antibody (McAB)
Industry, 2014
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com
with your contact details and questions if any.

• Published Jul 2014
• Single User License US 2000
• Corporate User License US 3000

2
2014 Monoclonal Antibody Chinese Industry
Research Report

• Research on China Monoclonal Antibody (McAB)
  Industry, 2014 mainly carries on in-depth
  analysis on policy environment, global market,
  Chinese market, as well as the latest
  developments of domestic key enterprises related
  to China's monoclonal antibody industry.
• Hengrui Medicine Co., Ltd., Shanghai
  Pharmaceuticals Co., Ltd. and Qilu Pharm have
  applied for clinical research of monoclonal
  antibody agents. And Walvax Biotechnology Co.,
  Ltd even made a huge investment in purchasing
  Genor Biopharma Co., Ltd, attempting to establish
  a large biological strategy. Although large-scale
  pharmaceutical enterprises entered monoclonal
  antibody field on a large scale, the overall
  innovation is still insufficient, and the market
  is represented by monoclonal antibody agents and
  biological analogue that have submitted
  applications, few imitated drugs, and innovative
  medicines are rare and precious things, mainly on
  account of high risks and long-time cycle.

Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
3
2014 Monoclonal Antibody Chinese Industry
Research Report

• Due to late state, China's strength on research
  and development will be still vulnerable within
  future three to five years, so it has to open the
  market preliminarily by depending on generic
  drugs. In 2013, the market size was CNY 3.8
  billion around, up 30 year-on-year product
  categories and sales volume were far less than
  that of European and American countries.
•  According to statistical data of Shanghai
  Pharmaceutical Profession Association (SPPA),
  China will see four to six monoclonal antibody
  agents by 2016, such as Trastuzumab and
  Rituximab. And it is expected by 2020, six to ten
  monoclonal antibody agents will be listed in
  market, and some of which are independently
  researched drugs. Huidian Research believes that
  China's monoclonal antibody market will embrace
  its first climax from 2017 to 2020.
• Inquiry before buying _at_
• http//www.reportsnreports.com/contacts/inquirybef
  orebuy.aspx?name296170 .

Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
4
2014 Monoclonal Antibody Chinese Industry
Research Report

• Table of Content
• Chapter One Overview of Monoclonal Antibody
• Chapter Two Operation Environment of China's
  Monoclonal Antibody Industry
• Chapter Current Situation and Tendencies of
  Worldwide Monoclonal Antibody Industry
• Chapter Four Operation Situation of China's
  Monoclonal Antibody Industry
• Chapter Five China's Key Monoclonal Antibody
  Agent Enterprises
• Chapter Huge Growth Potential and Development
  Opportunities of China Monoclonal Antibody Market
  in the Future
• Inquire for discount _at_ http//www.reportsnreports.
  com/contacts/discount.aspx?name296170 .

Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
5
2014 Monoclonal Antibody Chinese Industry
Research Report

• ReportsnReports.com  is your single source for
  all market research needs. Our database includes
  100,000 market research reports from over 95
  leading global publishers in-depth market
  research studies of over 5000 micro markets.

Get in touch with us at 1 888 391 5441 or Send
an email to sales_at_reportsandreports.com with your
contact details and questions if any.